Link investor

Seer Launches First-of-Its-Kind Proteogenomics Workflow to Link Genetic Modifications to Proteins… | Nation/World

REDWOOD CITY, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) — Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced a new proteogenomics workflow that integrates deep and unbiased proteomics with genomics, powered by Proteograph Analysis Suite 2.0, Seer’s software suite for data analysis and results visualization. The release of the workflow marks another milestone in Seer’s journey to enable precise, high-resolution, peptide-level proteogenomics at scale and follows the formation of his proteogenomics consortium in the first half of this year. .

Understanding the link between genes and proteins at the peptide sequence level is necessary to understand human health and disease, drive biomarker discovery, and enable the development of new therapies. Proteins dictate the body’s physiological response to disease and are in turn influenced by disease state. A single gene typically gives rise to multiple protein variants, such as splice variants, which may have distinct physiological roles and impact biology. Each protein variant gives rise to a different profile of peptides, which the Proteograph suite of products can identify and quantify, resolving known and new protein variants at the peptide level. Current affinity-based approaches study changes for a set of predefined protein targets, missing potentially important variants of these predefined proteins and providing an incomplete view of the relationship between genome and proteome.

Seer’s Proteograph Analysis Suite 2.0 is a key component of the Proteograph™ suite of products, which provides unbiased, deep, and rapid scale peptide-centric proteomics and enables high-resolution identification of protein variants. This next version of Proteograph Analysis Suite incorporates a proteogenomics workflow that maps peptide-level proteomics data to genomic data to identify sample-specific variant peptides not captured in canonical reference databases. The workflow summarizes results in interactive tables and plots, allows visualization of the relationship of identified peptides to gene structure, protein domain information and functional regions; and creates browsable peptide data maps at the amino acid level. Proteograph Analysis Suite’s intuitive visualizations make it faster and easier to discover target proteins for a wide range of applications.

“We are excited to offer PAS 2.0, this new proteogenomics workflow, and our other exciting future enhancements that make it easier for different customer groups to adopt in-depth and unbiased proteogenomics at scale,” said Serafim Batzoglou, Ph. .D., senior vice president. President, Data at Seer. “Making proteomic analysis tools more accessible to researchers is one of Seer’s top priorities, and today’s announcement is another step towards achieving that goal.”

The launch of the proteogenomics workflow reinforces Seer’s commitment to enabling broader access to proteogenomics tools. In January, Seer formed the Proteogenomics Consortium with Discovery Life Sciences, a world leader in the development of biomarkers and biological sample solutions using proteomics, genomics, cellular and immunohistochemical technologies, and SCIEX, a world leader in analytical technologies. life sciences. The collaboration aims to make it easier for genomics clients to add in-depth, unbiased proteomics data to their studies, enabling the discovery of novel protein variants and biomarkers that could lead to therapeutic breakthroughs.

“At Discovery Life Sciences, we are excited about the functionality we have seen demonstrated by this new tool and look forward to integrating the new features of Proteograph Analysis Suite 2.0 into our service pipeline at our new facility outside of Boston,” said Michael Pisano. , Ph.D., Executive Vice President, Proteomics at Discovery Life Sciences.

The rollout of Proteograph Analysis Suite v2.0 is underway, with Seer customers having immediate access to the software’s new workflow and features. For more information, visit https://seer.bio/PAS.

About LED

Seer is a life sciences company developing transformative products that open a new doorway to the proteome. Seer’s Proteograph™ product suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instruments and software to perform in-depth, unbiased large-scale proteomics analysis in hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted lab instruments to provide a decentralized solution that can be integrated by nearly any lab. Seer’s Proteograph product suite is intended for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.

Forward-looking statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements are based on Seer’s beliefs and assumptions and information currently available to it as of the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer’s actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include, but are not limited to, statements regarding the functionality and ability of Seer Proteograph Analysis Suite to enable accurate, high-resolution, large-scale peptide-level proteogenomics, and Seer’s collaboration with Discovery Life Sciences and SCIEX. These and other risks are described in greater detail in Seer’s filings with the Securities and Exchange Commission (“SEC”) and in other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update these statements to reflect events that occur or circumstances that exist after the date on which they were made.

Contact Investor

Carrie Mendivil

[email protected]

Media Contact

Karen Possemato

[email protected]

Copyright 2022 GlobeNewswire, Inc.